Androstanolon
DHT · DIHYDROTESTOSTERONE · ANDROSTANOLONE · 5α-Dihydrotestosterone · Andractim · 5α-DHT · 5α-androstan-17β-ol-3-one · Stanolon
Identifikatoren & physikalische Daten
| CAS No. | 521-18-6 |
|---|---|
| Summenformel | C19H30O2 |
| Durchschnittliche Molmasse | 290,4 g/mol |
| Monoisotopische Masse | 290,2245802 g/mol |
| SMILES | C[C@]12CCC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12 |
| InChIKey | NVKAWKQGWWIWPM-ABEVXSGRSA-N |
| PubChem CID | 10635 |
| ChEMBL | CHEMBL27769 |
| ChEBI | CHEBI:16330 |
| EC No. | 208-307-3 |
| DTXSID | DTXSID9022364 |
| Lokaler Name | Androstanolon |
Chemische & physikalische Eigenschaften
| XLogP | 3,7 |
|---|---|
| Polarare Oberfläche (TPSA) | 37,3 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 0 |
| Schwere Atome | 21 |
| Formalladung | 0 |
| Komplexität | 458 |
| Stoffklassen | Hormone |
| Arzneimittel | DEA NFLIS-Drug Category -> SteroidsDEA Schedule III Controlled Substance -> Anabolic steroidsPharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds |
| Lipide | Lipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C19 steroids (androgens) and derivatives [ST0202] |
| SpringerMaterials Properties | Chemical shift |
| LogP (Verteilungskoeffizient) | 3.55 |
| Human Drugs | Pharmaceuticals |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Schmelzpunkt | 181 °C178-183 °C |
| Physical Description | Solid |
| Collision Cross Section | 177.31 Ų [M+H]+ |
| Siedepunkt | 372.52°C (rough estimate) |
| Dichte | 1.0320 (rough estimate) |
| Brechungsindex | 1.4709 (estimate) |
| Flammpunkt | 9℃ |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | Acetonitrile: 1 mg/mlEthanol: 1 mg/mlMethanol: 1 mg/ml344.3g/L(temperature not stated) |
| pKa (Säurekonstante) | 15.08±0.60(Predicted) |
| Aggregatzustand | powder |
| Biologische Quelle | synthetic |
| Merck | 13,8872 |
| BRN | 2056371 |
| Hauptanwendungen | forensics and toxicologypharmaceutical (small molecule) |
| InChI | 1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1 |
| InChIKey | NVKAWKQGWWIWPM-ABEVXSGRSA-N |
| SMILES | [H][C@@]12CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CCC(=O)C2 |
| CAS Datenbank | 521-18-6(CAS DataBase Reference) |
| NIST chemische Informationen | Stanolone(521-18-6) |
| EPA chemische Informationen | Androstan-3-one, 17-hydroxy-, (5.alpha.,17.beta.)- (521-18-6) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH351 (98.3%): Suspected of causing cancer [Warning Carcinogenicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 60 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | DEA schedule III controlled substanceStatus: Cease Manufacture Update: 31-10-2012 https://echa.europa.eu/registration-dossier/-/registered-dossier/12136 |
| Hazard Classes and Categories | Carc. 2 (98.3%) |
| Expositionspfade | Bioavailability is very low (0-2%) following oral administration. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)ANDROSTANOLONEDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| USGS Health-Based Screening Levels for Evaluating Water-Quality | DihydrotestosteroneHormoneSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN1230 - class 3 - PG 2 - Methanol, solution |
| RTECS-Nr. | BV8052000 |
| R-Sätze (R) | 61-40-39/23/24/25-23/24/25-11 |
| Gefahrensymbole | Xn,T,F |
| Sicherheitshinweise (S) | 53-36/37/39-45-36/37-16 |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1Carc. 2Repr. 1A |
Anwendungen & Verwendung
Beschreibung
Stanolone is well known as dihydrotestosterone (DHT), which is an endogenous androgen sex steroid and hormone. It is an agonist of the androgen receptor (AR). It plays important physiological role in sexual differentiation, maturation of the penis and scrotum, hair, sebum production and development and maintenance of the prostate gland and seminal vesicles. It is mainly used for the treatment of male hypogonadism, androgen deficiency of severe illness, androgen deficiency of ageing and microphallus in infancy.
Verwenden
Stanolone is a potent androgenic metabolite of testosterone that It is Controlled substance. It was created for the treatment of muscle wasting disease, and osteoporosis. It is a powerful anabolic steroid, which is similar to the body's naturally produced Dihydrotestosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.